Haematological side effects of antiepileptic drug treatment in patients with epilepsy

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 191, 2011, Pages 23-27

  Bachmann, T ^a   Bertheussen, K H ^a   Svalheim, S ^a   Rauchenzauner, M ^b   Luef, G ^b   Gjerstad, L ^a,c   Tauboll E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Carbamazepine; Haematology; Haemoglobin; Lamotrigine; Leucocytes; Levetiracetam; Thrombocytes; Valproate

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; HEMOGLOBIN; LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; AUSTRIA; CONTROLLED STUDY; DRUG EFFECT; EPILEPSY; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NORWAY; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE COUNT;

EID: 79960034288     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01539.x     Document Type: Article

References (19)

1. Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurother 2010;10:159-71.
2. Kimland E, Höjeberg B, Von Euler M. Levetiracetam induced thrombocytopenia. Epilepsia 2004;45:877-8.
3. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 2003;4:2079-88.
4. Meschede A, Runge U, Sabolek M. Thrombocytopenia during levetiracetam therapy. Epilepsy Res 2008;80:91-2.
5. Hartmann H, Schumacher U, Seeck M. Verschlechterung einer Immunthrombopenie unter Monotherapie mit Levetiracetam. Akt Neurol 2002;29:467-8.
6. Herrman H, Taubøll E, Gjerstad L Levetiracetam-induced thrombocytopathia. American Epilepsy Society Meeting, San Diego, 2006.
7. Sahaya K, Goyal MK, Sarwal A, Singh NN. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 2010;51:2492-5.
8. Ural AU, Avcu F, Gökcil Z, Nevruz O, Cetin T. Leucopenia and thrombocytopenia possible associated with lamotrigine use in a patient. Epileptic Disord 2005;7:33-5.
9. Allan RW. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature. Hematology 2007;12:493-6.
10. Acharya S, Bussel J. Hematologic toxicity of Sodium Valproate. J Pediatr Hematol Oncol 2000;22:62-5.
11. Handoko KB, Souverein PC, Van Staa TP et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006;47:1232-6.
12. Harden CL. Therapeutic safety monitoring-what to look for and when to look for it. Epilepsia 2000;41:37-44.
13. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol 1982;11:309-12.
14. Sobotka JL, Alexander B, Cook BL. A review of Carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990;24:1214-9.
15. Patsalos PN, Fröscher W, Pisani F, Van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85.
16. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008;49:438-45.
17. Tohen M, Castillo J, Cole JO, Miller MG, De Los HEROS R, Farrer RJ. Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry 1991;52:496-8.
18. Bauer J, Ben-Menachem E, Krämer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenité DG. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 2006;114:169-76.
19. Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004;101:9861-6.